argenx SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of argenx SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $528.16.

Several research firms recently weighed in on ARGX. HC Wainwright restated a “buy” rating and issued a $451.00 price objective on shares of argenx in a research report on Thursday, April 18th. Wedbush reiterated an “outperform” rating and set a $521.00 target price on shares of argenx in a research report on Thursday, April 18th. JMP Securities reiterated a “market outperform” rating and set a $471.00 target price on shares of argenx in a research report on Friday, March 22nd. Robert W. Baird dropped their target price on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Finally, Wells Fargo & Company upped their target price on shares of argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th.

argenx Price Performance

ARGX stock opened at $375.08 on Wednesday. The company has a 50 day moving average price of $386.95 and a 200 day moving average price of $419.33. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The stock has a market capitalization of $22.29 billion, a PE ratio of -72.97 and a beta of 0.65.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The company had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. During the same quarter last year, the firm earned ($0.70) EPS. As a group, equities analysts expect that argenx will post -2.1 earnings per share for the current fiscal year.

Institutional Trading of argenx

Large investors have recently made changes to their positions in the company. Nkcfo LLC boosted its stake in argenx by 22.1% in the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after purchasing an additional 21 shares during the period. Genus Capital Management Inc. boosted its stake in argenx by 1.6% in the 3rd quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock worth $789,000 after purchasing an additional 25 shares during the period. Wahed Invest LLC boosted its stake in argenx by 9.6% in the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after purchasing an additional 40 shares during the period. Daiwa Securities Group Inc. boosted its stake in argenx by 2.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock worth $582,000 after purchasing an additional 41 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in argenx by 3.1% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after purchasing an additional 43 shares during the period. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.